Salud financiera de hoja de balance de Nanobiotix

Salud financiera controles de criterios 2/6

Nanobiotix tiene un patrimonio de los accionistas total de €-1.8M y una deuda total de €0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son €93.9M y €95.7M respectivamente.

Información clave

-2,467.9%

Ratio deuda-patrimonio

€45.48m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	€75.28m
Patrimonio	-€1.84m
Total pasivo	€95.74m
Activos totales	€93.90m

Actualizaciones recientes sobre salud financiera

Recent updates

We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

Apr 26

Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

May 11

Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Dec 06

Is Nanobiotix (EPA:NANO) Using Too Much Debt?

Jun 04

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

Dec 22

Análisis de la situación financiera

Pasivos a corto plazo: NANO tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: NANO tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: NANO tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: NANO tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: NANO tiene suficiente cash runway para más de 3 años basándose en su flujo de caja libre actual.

Pronóstico de cash runway: NANO dispone de suficiente cash runway para 2 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 1.4% cada año.

Salud financiera de hoja de balance de Nanobiotix

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Is Nanobiotix (EPA:NANO) Using Too Much Debt?

Recent updates

New minor risk - Profitability

Forecast to breakeven in 2026

Nanobiotix S.A. to Report Q4, 2023 Results on Apr 24, 2024

Consensus revenue estimates fall by 24%

Nanobiotix S.A. announced that it has received $24.999999 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. to Report Q3, 2023 Results on Nov 13, 2023

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $29.288592 million.

Nanobiotix S.A. has filed a Follow-on Equity Offering in the amount of $30 million.

Nanobiotix S.A. announced that it expects to receive $25 million in funding from Johnson & Johnson Innovation - JJDC, Inc.

Nanobiotix S.A. Announces Updated Preliminary Results from Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis from Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023

Consensus revenue estimates increase by 26%

Nanobiotix S.A. Announces New Clinical Data from Phase 1 Study Evaluating Radiotherapy-Activated Nbtxr3 for Patients with Pancreatic Ductal Adenocarcinoma

New minor risk - Financial position

Nanobiotix S.A. to Report First Half, 2023 Results on Sep 26, 2023

New minor risk - Shareholder dilution

NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3

Nanobiotix S.A. Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers

Consensus revenue estimates increase by 420%

Price target increased by 23% to €19.03

Nanobiotix S.A., Annual General Meeting, Jun 27, 2023

No longer forecast to breakeven

Price target increased by 15% to €25.17

We're Keeping An Eye On Nanobiotix's (EPA:NANO) Cash Burn Rate

NANOBIOTIX Announces First Patient Randomized in United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer

Price target decreased to €21.90

NANOBIOTIX Recommends Phase 2 Dose for NBTXR3 in Pancreatic Cancer

NANOBIOTIX Updates Data from its Phase 1 Immunotherapy Study, Study 1100

NANOBIOTIX Announces the Appointment of Global Medical Experts to Scientific Advisory Board

Forecast to breakeven in 2024

NANOBIOTIX Establishes Recommends Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy

Nanobiotix S.A. and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces the Reporting of New Data at the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces the Reporting of New Data At the 2022 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. to Report First Half, 2022 Results on Sep 28, 2022

Is Nanobiotix (EPA:NANO) Weighed On By Its Debt Load?

Price target decreased to €22.90

Nanobiotix S.A. Announces New Data from an Open-Label Preclinical Study Evaluating the Combination of First-in-Class Radioenhancer, NBTXR3, with the Triple Blockade of PD-1, LAG-3, and TIGIT

Price target decreased to €23.18

Full year 2021 earnings: EPS and revenues miss analyst expectations

Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer

Price target increased to €29.67

Nanobiotix S.A. Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4

Nanobiotix S.A. Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer

Nanobiotix (EPA:NANO) Has Debt But No Earnings; Should You Worry?

Nanobiotix S.A. Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May 'Reprogram' the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect

First half 2021 earnings released: €0.88 loss per share (vs €0.91 loss in 1H 2020)

NANOBIOTIX Announces Initiation of New Clinical Study Evaluating NBTXR3 in Lung Cancer

NANOBIOTIX Reports New Data for Potential First-in-Class Radioenhancer NBTXR3 in Combination With Anti-PD-1 Showing Local or Distant Tumor Regression in 76.9% of Evaluable Patients Regardless of Prior Anti-PD-1 Exposure

Is Nanobiotix (EPA:NANO) Using Too Much Debt?

Nanobiotix Announces Updated Results From Priority Pathways in Head and Neck Cancer and Immunotherapy for Potential First-in-class Radioenhancer NBTXR3 at 2021 Annual Meeting of the American Society for Clinical Oncology

Nanobiotix S.A. Announces New Data from its Oncology Pipeline to Be Present at the 2021 American Society of Clinical Oncology Annual Meeting

Consensus EPS estimates fall to -€1.29

Full year 2020 earnings released: €1.38 loss per share (vs €2.35 loss in FY 2019)

Full year 2020 earnings released

NANOBIOTIX and PharmaEngine, Inc. Mutually Agree to Conclude Collaboration

NANOBIOTIX Announces Positive New Preclinical Data Investigating First-In-Class Radioenhancer NBTXR3

Nanobiotix S.A. to Report Q2, 2021 Results on Sep 03, 2021

Nanobiotix Announces First Patient Injected with NBTXR3 in Esophageal Cancer

New 90-day high: €17.20

NANOBIOTIX Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021

Price target raised to €25.18

How Should Investors React To Nanobiotix's (EPA:NANO) CEO Pay?

New 90-day high: €14.00

Nanobiotix S.A. has completed a Follow-on Equity Offering in the amount of $99 million.

Analysts update estimates

Nanobiotix Announces Two New Phase II Trials Evaluating NBTXR3 in Combination with Anti-PD-1 for the Treatment of Head and Neck Cancer

NANOBIOTIX Announces Positive New Pre-Clinical Data Suggesting Radioenhancer NBTXR3 Could Have A Significant Impact in Immunotherapy

Nanobiotix Announces Positive First Clinical Data Showing Conversion of Anti-PD-1 Non-Responders to Responders With Radioenhancer NBTXR3

New 90-day low: €5.72

Nanobiotix Provides Updates on Global Clinical Development Plan for First-In-Class Radioenhancer Nbtxr3 At Astro 2020

NANOBIOTIX Announces First Patient Injected with Nbtxr3 in Pancreatic Cancer and Safe to Proceed Notifications for Two Additional Trials from U.S. FDA